Director continue accumulating

WCT is theme of recovery

Iwcity landbank are all located in prime either seafronting or riverfronting near causeway, about 5 min from recent approved RTS station. With RTS linking direct to Singapore, it will boost surrounding development.

Iwcity land disposal worth RM 2.3 billion still ongoing, on staggering basis to unlock land value forward.

Many still wish to wait for topglove skyrocket result next week. But, take a look what happen to other glove stock after release skyrocket Q result?

The earning already all price in stock price, and selloff start after Q result release as shown by many glove stock

Many still wish to wait for topglove skyrocket result next week. But, take a look what happen to other glove stock after release skyrocket Q result?

The earning already all price in stock price, and selloff start after Q result release as shown by many glove stock

Awaken, many know ahead that glove skyrocket is covid driven. It is temporary phenomena due to Full speed of global force in vaccine development, arrow-shape type of profit, unsustainable.

Many know have to sell before pandemic is over. But, many other also smart enough to sell ahead of peak earning if compared to those already fall in love in glove stock force to follow selloff late later.....viscous cycle ahead

Awaken, many know ahead that glove skyrocket is covid driven. It is temporary phenomena due to Full speed of global force in vaccine development, arrow-shape type of profit, unsustainable.

Many know have to sell before pandemic is over. But, many other also smart enough to sell ahead of peak earning if compared to those already fall in love in glove stock force to follow selloff late later.....viscous cycle ahead

Arrow-shape profit, earning will be peak in next Q result. Unsustainable ASP hike

Arrow-shape profit, earning will be peak in next Q result. Unsustainable ASP hike

US, the world largest covid case have gradually under control, the daily new case is on downtrend.

https://www.worldometers.info/coronavirus/country/us/

US, the world largest covid case have gradually under control, the daily new case is on downtrend.

https://www.worldometers.info/coronavirus/country/us/

Recent Fundamental change in topglove

1. Currency exchange, USD have weakness from 4.3 in to current 4.15
2. Feedstock cost increase, synthetic rubber price hike due to shortage.
3. Labor cost increase, salary, accommodation and reimbursement
4. Banning export to US, the largest market since July, sales volume unable to realize, re route sales involve logistic cost
5. Banning export to US, loss highest profit margin market as US command premium selling price.

China's nationalistic tabloid Global Times reported last month that "the price of the vaccines will not be high."

Every two doses should cost below 1,000 yuan (US$146), the report said, citing Sinopharm's chairman, who told media he has already been injected with one of the candidate vaccines.

China's official Xinhua news agency reported on Monday that another vaccine candidate, developed by Chinese military scientists, can deal with mutations in the coronavirus.

As of last month, at least 5.7 billion doses of the vaccines under development around the world had been pre-ordered.

China's nationalistic tabloid Global Times reported last month that "the price of the vaccines will not be high."

Every two doses should cost below 1,000 yuan (US$146), the report said, citing Sinopharm's chairman, who told media he has already been injected with one of the candidate vaccines.

China's official Xinhua news agency reported on Monday that another vaccine candidate, developed by Chinese military scientists, can deal with mutations in the coronavirus.

As of last month, at least 5.7 billion doses of the vaccines under development around the world had been pre-ordered.

Although no. of shipment during a specific time frame is only an indicator. It does not represent the absolute sales result in a market.

But, please take note, the decreasing import from supermax happen is at time US ban global top largest Top glove import glove in July. Theoretically, banning gloval largest glove maker since July should translate to significant higher import from other glove maker to substitute absent market share from topglove. But, in contrast, US also reduce significantly glove volume from supermax till now.

Do you think its good news for supermax ?

Some said should compared to last year volume......No, you should compared consecutive volume during covid pandemic time instead of compared last year nil pandemic time. No point to compared glove demand in pandemic vs. non pandemic.

Some said use old data to confuse? but supermax healthcare import is update on weekly basis. The decreasing trend should serve as early warming instead of still fall deep in past record when data should peak demand in May

https://importkey.com/i/supermax-healthcare-inc

KUALA LUMPUR: 48 per cent of Malaysians surveyed think a vaccine for Covid-19 would be made available to them by the end of the year.

This makes Malaysians more optimistic than the global average, found an Ipsos survey for the World Economic Forum.

"Malaysia and China are two very confident countries that believe the Covid-19 vaccine will be available by the end of the year while other Western countries have little hope of it," said the market research company.

The survey - Attitude on Covid 19 Vaccine, found that China was the most optimistic at 87 per cent, while most Western countries and Japan were less optimistic about the prospects of a vaccine being found for the novel coronavirus by the end of 2020.
You May Also Like

Even with vaccine, battle against Covid-19 will last years
China Covid-19 vaccine approved - for its military
'Little chance of Covid-19 vaccine by 2021'
Putin: Russia has developed 'first' Covid-19 vaccine

Although the discovery of the vaccine seems to build an excitement, nevertheless almost half of the Malaysians surveyed were concerned about the side effects such a vaccine might leave behind, Ipsos said.

It adds that the survey also found that a third of Malaysians refuse to think that the vaccine would be effective, while a good number of them were optimistic that they would not be at risk from Covid-19 and as such they would not find it necessary to get the shot.

"As countries and companies push against time to release a Covid-19 vaccine, public opinion and acceptability also play an important role in its success.

"Malaysians stand with the emerging economies, in their optimism for an early availability of Covid-19 vaccine.

"Universal and affordable public health care system support Malaysians' confidence in the availability of vaccine for the masses," Managing director of IPSOS Malaysia, Arun Menon said.

He stressed that public authorities should be conscious about the general apprehension on side effects and vaccine effectiveness as potential barriers of adoption.

KUALA LUMPUR: 48 per cent of Malaysians surveyed think a vaccine for Covid-19 would be made available to them by the end of the year.

This makes Malaysians more optimistic than the global average, found an Ipsos survey for the World Economic Forum.

"Malaysia and China are two very confident countries that believe the Covid-19 vaccine will be available by the end of the year while other Western countries have little hope of it," said the market research company.

The survey - Attitude on Covid 19 Vaccine, found that China was the most optimistic at 87 per cent, while most Western countries and Japan were less optimistic about the prospects of a vaccine being found for the novel coronavirus by the end of 2020.
You May Also Like

Even with vaccine, battle against Covid-19 will last years
China Covid-19 vaccine approved - for its military
'Little chance of Covid-19 vaccine by 2021'
Putin: Russia has developed 'first' Covid-19 vaccine

Although the discovery of the vaccine seems to build an excitement, nevertheless almost half of the Malaysians surveyed were concerned about the side effects such a vaccine might leave behind, Ipsos said.

It adds that the survey also found that a third of Malaysians refuse to think that the vaccine would be effective, while a good number of them were optimistic that they would not be at risk from Covid-19 and as such they would not find it necessary to get the shot.

"As countries and companies push against time to release a Covid-19 vaccine, public opinion and acceptability also play an important role in its success.

"Malaysians stand with the emerging economies, in their optimism for an early availability of Covid-19 vaccine.

"Universal and affordable public health care system support Malaysians' confidence in the availability of vaccine for the masses," Managing director of IPSOS Malaysia, Arun Menon said.

He stressed that public authorities should be conscious about the general apprehension on side effects and vaccine effectiveness as potential barriers of adoption.

https://www.nst.com.my/news/nation/2020/09/622528/survey-shows-many-optimistic-covid-19-vaccine-will-be-available

https://www.theedgemarkets.com/article/almost-half-malaysians-confident-vaccine-will-be-available-2020-%E2%80%94-ipsos

https://www.theedgemarkets.com/article/almost-half-malaysians-confident-vaccine-will-be-available-2020-%E2%80%94-ipsos

Almost half of Malaysians confident vaccine will be available in 2020 — Ipsos

KUALA LUMPUR (Sept 7): Almost half of Malaysians, or 48%, trust that a vaccine will be available to them before the end of the year, ahead of the global average.

In a recent Ipsos survey for the World Economic Forum released recently, China emerged as the most optimistic with a total of 87% while Japan appears to be the most pessimistic with only 22% of its people agreeing to the possibility of a vaccine available to them.

In a statement, Ipsos managing partner Arun Menon said as countries and companies push against time to release a Covid-19 vaccine, public opinion and acceptability play the most important role in its success.

Menon said a universal and affordable public health care system supports Malaysian confidence in the availability of vaccines for the masses.

As a result of respective governments and health authorities’ rapid push for the production of a vaccine for Covid-19, there are increasing and valid doubts over its side effects and effectiveness.

In determining more specificities of the aforementioned, the Ipsos survey also conducted a search on possible reasons Malaysians would not take the vaccine for Covid-19.

The results of the survey show that the top reason is indeed the public’s worry about the vaccine’s potential side effects.

However, the next reason in line, with 36% of the population on board, is the opinion that they are not at risk from Covid-19.

It is notable that Malaysians are much more confident of being free from the risks from Covid-19 as compared to the global average (19%).

The third reason differs from that of the global average as well, which is the disbelief that the vaccine will be effective (29%).

However, even for this reason, Malaysia stands at a slightly higher percentage than the average with a total of 33% of its population believing so.

Menon said public authorities should be conscious about the general apprehension on side effects and vaccine effectiveness as potential barriers of adoption.


https://www.theedgemarkets.com/article/almost-half-malaysians-confident-vaccine-will-be-available-2020-%E2%80%94-ipsos

Glove export to US on decreasing trend. The US market peak demand already reached in May, thereafter, already on decreasing demand from supermax.

Please take note, the decreasing import from supermax happen is at time US ban Top glove in July.

Theoretically, US covid case surge up significantly in July til now, and banning glove from top glove since July should translate to significant leap up higher import from other glove maker to substitute absent market share from topglove.

But, in contrast, US also reduce significantly glove volume from supermax till now.

The only justifiable RATIONALE is US glove market also reached Peak demand in last May, and on decreasing trend even after take into account surge in covid case + banning topglove from entry to US since july

https://importkey.com/i/supermax-healthcare-inc


Remark: US is largest import market and US market command highest ASP premium if compared to any other country.

Glove export to US on decreasing trend. The US market peak demand already reached in May, thereafter, already on decreasing demand from supermax.

Please take note, the decreasing import from supermax happen is at time US ban Top glove in July.

Theoretically, US covid case surge up significantly in July til now, and banning glove from top glove since July should translate to significant leap up higher import from other glove maker to substitute absent market share from topglove.

But, in contrast, US also reduce significantly glove volume from supermax till now.

The only justifiable RATIONALE is US glove market also reached Peak demand in last May, and on decreasing trend even after take into account surge in covid case + banning topglove from entry to US since july

https://importkey.com/i/supermax-healthcare-inc


Remark: US is largest import market and US market command highest ASP premium if compared to any other country.

US is top 4 largest glove maker in Msia. Top glove export about 25% volume to US market, but, US have ban topglove export since July. Although other country can fill up demand, but US market command highest ASP premium if compared to any other country.

Glove export to US on decreasing trend. Take supermax healthcare data, The US market peak demand already reached in May, thereafter, already on decreasing demand from supermax.

https://importkey.com/i/supermax-healthcare-inc

US is supermax largest export market and US market command highest ASP premium if compared to any other country.

Glove export to US on decreasing trend. The US market peak demand already reached in May, thereafter, already on decreasing demand from supermax.

https://importkey.com/i/supermax-healthcare-inc

Glove export to US on decreasing trend

https://importkey.com/i/supermax-healthcare-inc

CPO price RM 2941

US second stimulus package is ready to present by 12 Sept, printing more money to stimulus US economy, boost economy activity, stimulus gasoline demand

CPO price still above RM 2900

Carimin is NET CASH company, about half of the current price is back by CASH hoard.

US second stimulus package by 12 Sept + vaccine available as early Oct in US = crude oil price to CONTINUE recover back.

Initial jobless claims, week ended Aug. 29: 881,000 vs. 950,000 expected

Continuing claims, week ended Aug. 22: 13.254 million vs. 14.000 million expected

By 12 Sept, US second stimulus packager will announce, boosting further recovery economy + vaccine ready as early as next month = demand US gasoline will increasing

US second stimulus package + vaccine available as early Oct in US = crude oil price to recover back.

Brent crude oil have recover from as low as USD 30 to current level USD 43-46. These is more than 40% recover. Hibiscus selling crude oil on average USD 31 in its latest Q result.

As show in chart, Brent crude oil major resistance level is at USD46, it have many attempt to break through these level, retrace back now to support level USD 43. It’s still range bound trading, awaiting major catalyst, US second stimulus by 12 Sept.

US second stimulus package + vaccine available as early Oct in US = crude oil price to recover back.

Brent crude oil have recover from as low as USD 30 to current level USD 43-46. These is more than 40% recover. Hibiscus selling crude oil on average USD 31 in its latest Q result. As show in chart, Brent crude oil major resistance level is at USD46, it have many attempt to break through these level, retrace back now to support level USD 43. It’s still range bound trading, awaiting major catalyst, US second stimulus by 12 Sept.

Hibiscus crude oil selling price is USA 31.8 in previous Q result.
The curent brent crude oil market price is USD 43-46, these is a massive increment above 40%. As cost is relatively fixed, any surplus above cost is PURE PROFIT

Hibiscus just announce get award 3 new producing oil block in UK, capacity expansion forward

Inside China's new lab conducting late-stage Covid-19 vaccine trials
CNN's David Culver takes us inside a brand new vaccine lab in China and speaks to scientists there about how close they are to a coronavirus vaccine.

https://youtu.be/N8a2RZqpeTE

Inside China's new lab conducting late-stage Covid-19 vaccine trials
CNN's David Culver takes us inside a brand new vaccine lab in China and speaks to scientists there about how close they are to a coronavirus vaccine.

https://youtu.be/N8a2RZqpeTE

US already confrim to get vaccine as early as next month, OCT. Vaccine is OPPOSITE correlate with glove

https://www.theedgemarkets.com/article/us-cdc-tells-states-prep-covid19-vaccine-distribution-nov

US already confrim to get vaccine as early as next month, OCT. Vaccine is OPPOSITE correlate with glove

https://www.theedgemarkets.com/article/us-cdc-tells-states-prep-covid19-vaccine-distribution-nov

ahpooki2

Local pharma profit margin on vaccine is small as it is patent for production.

US CDC tells states to prep for Covid-19 vaccine distribution by November
September 03, 2020 06:49 am +08

(Sept 3): The U.S. Centers for Disease Control and Prevention (CDC) has asked state public health officials to prepare to distribute a potential coronavirus vaccine to high-risk groups as soon as late October or early November, documents published by the agency showed on Wednesday.

The timing of release of any vaccine has taken on political importance as U.S. President Donald Trump seeks re-election in November, after putting substantial federal resources into vaccine development.

"For the purpose of initial planning, CDC provided states with certain planning assumptions as they work on state specific plans for vaccine distribution, including possibly having limited quantities of vaccines in October and November," a CDC spokeswoman told Reuters.

The New York Times had earlier reported that the CDC had contacted officials in all 50 states and five large cities with the documents.

The country's top infectious disease expert Anthony Fauci earlier on Wednesday said on MSNBC that based on the patient enrollment rate in COVID-19 vaccine trials underway, there could be enough clinical data to know by November or December that one of the vaccines is safe and effective.

The documents put online by the New York Times showed that the CDC is preparing for one or two vaccines for COVID -19 to be available in limited doses as soon as late October.

The vaccines may be available free of cost first to high-risk groups including health care works, national security personnel, residents and staff at COVID-19 long-term care facilities, the agency said in the documents.

Drug developers including Moderna Inc, AstraZeneca Plc and Pfizer Inc are leading the race to develop a safe and effective vaccine for the respiratory illness.

The documents describe two vaccine candidates that must be stored at temperatures of -70 and -20 degrees centigrade. Those storage requirements match profiles of candidates from Pfizer and Moderna.

https://www.theedgemarkets.com/article/us-cdc-tells-states-prep-covid19-vaccine-distribution-nov

US CDC tells states to prep for Covid-19 vaccine distribution by November
September 03, 2020 06:49 am +08

(Sept 3): The U.S. Centers for Disease Control and Prevention (CDC) has asked state public health officials to prepare to distribute a potential coronavirus vaccine to high-risk groups as soon as late October or early November, documents published by the agency showed on Wednesday.

The timing of release of any vaccine has taken on political importance as U.S. President Donald Trump seeks re-election in November, after putting substantial federal resources into vaccine development.

"For the purpose of initial planning, CDC provided states with certain planning assumptions as they work on state specific plans for vaccine distribution, including possibly having limited quantities of vaccines in October and November," a CDC spokeswoman told Reuters.

The New York Times had earlier reported that the CDC had contacted officials in all 50 states and five large cities with the documents.

The country's top infectious disease expert Anthony Fauci earlier on Wednesday said on MSNBC that based on the patient enrollment rate in COVID-19 vaccine trials underway, there could be enough clinical data to know by November or December that one of the vaccines is safe and effective.

The documents put online by the New York Times showed that the CDC is preparing for one or two vaccines for COVID -19 to be available in limited doses as soon as late October.

The vaccines may be available free of cost first to high-risk groups including health care works, national security personnel, residents and staff at COVID-19 long-term care facilities, the agency said in the documents.

Drug developers including Moderna Inc, AstraZeneca Plc and Pfizer Inc are leading the race to develop a safe and effective vaccine for the respiratory illness.

The documents describe two vaccine candidates that must be stored at temperatures of -70 and -20 degrees centigrade. Those storage requirements match profiles of candidates from Pfizer and Moderna.

https://www.theedgemarkets.com/article/us-cdc-tells-states-prep-covid19-vaccine-distribution-nov

bought ekovest at 49.5sen

bought carimin at 63-63.5sen

bought IWCITY at 58.5-59sen

sold all IJM at 1.35

sustain above RM 1.36 is crucial for trend REVERSAL

Pchemcial is good proxy for Petronas, benefited from recovery in crude oil. Strong balance sheet with net cash position + dividend policy 55% offer limited downside risk.

LCtitan expansion in Indonesia is timely, benefited from Indonesia currency strengthen against USD.

Immediate resistance level at 1.36. Once IJM successful breakthrough these level, reversal trend is confirm, on track back to recover above RM 1.60

Current weakness in USD is good for LCtitan, as all its feedstock are USD denominated, but product sale is local currency denominated, mainly in Msia, China, Indonesia.